Receptor Logic Chief Scientist to Speak At FOCIS Immunology Conference
Amarillo, TX, and Austin, TX - June 5th, 2007 - Receptor Logic, Inc. of Amarillo announced today that its Chief Scientist, Dr. Jon Weidanz, will speak at the Federation of Clinical Immunology Societies, (“FOCIS”) Annual Meeting on June 9th in San Diego.
Mr. Tony Taylor, Receptor Logic Managing Director, commented, "We are delighted that Dr. Weidanz was selected to present our technology in a talk entitled, ‘Improving targeted immunotherapy through direct validation of peptide-MHC epitopes using TCRm antibodies’. We continue to demonstrate the powerful science behind our patented antibody technology." Dr. Weidanz will also be presenting a poster entitled, ‘Optimizing peptide loading of dendritic cells using TCRm antibodies’. This research, which may lead to better diagnosis and treatment of diseases such as cancer, was funded through an award from the Advanced Technology Program, an agency of the National Institute of Standards and Technology.
Mr. John Hoopingarner, COO of Receptor Logic, commented, "The annual FOCIS meeting highlights the best science in the field of clinical immunology, and Dr. Weidanz’ work will certainly reflect our scientific leadership to the many biopharma industry representatives attending this meeting." More information about the FOCIS meeting is found at www.focisnet.org.
Receptor Logic, launched in December of 2003, is managed by Emergent Technologies, Inc. (ETI) and funded through its third fund, WesTech Ventures I, L.P.
About Receptor Logic, Inc.
Receptor Logic is a biopharmaceutical company specializing in high-quality antibodies that mimic the specificity of T-Cell Receptors in the immune system. These T-Cell Receptor mimics (TCRm’s) offer valuable insight into how the immune system interacts with a diseased cell, yielding better immunology research, better clinical diagnostics, and better therapies such as monoclonal antibodies and vaccines. For more information, visit the company website www.receptorlogic.com.
About Emergent Technologies, Inc.
Emergent Technologies Inc. (ETI), founded in 1989 by Thomas A. Harlan, is a unique life sciences venture firm that forms and manages companies and funds that commercialize groundbreaking institutional and university-based technologies. ETI is a turnkey solution for converting university science into high return ventures. ETI works with regional economic development groups and universities to capitalize on the technology assets unique to their region. For more information, visit the company website www.etibio.com
Contact: Mr. Tony Taylor
2508 Ashley Worth Blvd., Suite 200
Austin, TX 78738
(T) 512/697-8210 (F) 512/263-3236
KEYWORD: Austin, Amarillo
INDUSTRY KEYWORD: IMMUNOTHERAPY PHARMACEUTICAL ANTIBODY BIOTECH BREAST CANCER HLA MHC T-CELL ATP NIST